contact@pnhca.org

Blog

Changes to Canada’s Drug Pricing Guidelines Will Hit Rare Disease Patients Hardest

Another article from Canadian health economists concludes that the proposed changes to the Patented Medicine Prices Review Board (PMPRB) guidelines, which come into effect in July 2020, will discourage drug companies from bringing their products to Canada. The revised PMPRB guidelines make no exceptions for therapies to treat rare disorders or other specialized medicines. The worst outcomes are predicted to be significantly reduced access to all new therapies for those patients with either public or private insurance, as well as long delays in accessing new treatment options for rare diseases like PNH.

For the full article, please visit: https://www.canadianhealthpolicy.com/products/new-patented-medicine-regulations-in-canada–updated-case-study-.html